Dementia screening for the hearing impaired

Published Date: 08 Mar 2023

Researchers at the University of Queensland have adapted a test used around the world to screen people with dementia and Alzheimer's disease to make it suitable for people with hearing loss.

Read Full News

Latest News

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

News All Time

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

This Week on NeurologyLive® — February 9, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again Noah Stansfield

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

AGNOS Study Results Demonstrate Ofatumumab’s Impact on Neurofilament Light, GFAP Marco Meglio

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

International Epilepsy Day 2026: Highlighting Gaps in Pediatric Care, Stigma, and Education Charuta Joshi, MD, Isabella Ciccone, MPH

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents amid International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL Noah Stansfield

The FDA issued a CRL for gene therapy RGX-121 in Hunter syndrome, citing trial design and biomarker doubts; Regenxbio seeks a meeting with the agency and resubmission.

NeurologyLive® Friday 5 — February 6, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.

Comparative Study Reveals Psychiatric Comorbidities Common in MOGAD, MS, and NMOSD, With Distinct Timing Patterns Isabella Ciccone, MPH

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

Cladribine Tablets Reduce Treatment Switches, Outpatient Visits, and Health Care Costs in Multiple Sclerosis Isabella Ciccone, MPH

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

Innovative Trial Employs Novel PET Imaging to Track Cladribine’s Effect on Microglial Activation Louie Pasculli

The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.

Recommended News For You

Asymptomatic or Minimally Symptomatic Myelofibrosis

novel approach to test the toxicity of cancer drugs.

A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

High numbers of rural patients cross state lines for cancer care

Prostate cancer screening program beneficial in top decile of polygenic risk score

Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes

Recommended Articles For You

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies 

The Science Behind Thrombolytic Drugs and Their Benefits  

Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources 

Uncovering the Secrets of CA19-9: A Blood Test for Cancer Diagnosis 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Prior Authorization Be Better With Artificial Intelligence?

2.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

3.

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

4.

No increased risk of childhood cancer near UK nuclear sites, study finds

5.

A promising medication could slow brain tumors in children.

1.

Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations

2.

How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies

3.

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

4.

Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections

5.

Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

2.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot